Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP6 | P55212 | 1/20 | 0.58 |
| ▸ | TSHR | P16473 | 2/20 | 0.58 |
| ▸ | HCAR3 | P49019 | 11/20 | 0.58 |
| ▸ | LMNA | P02545 | 2/20 | 0.54 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | APEX1 | P27695 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13264670 | 0.88 | CASP6 (0.55) | CASP6TSHRHCAR3LMNAMAPT | |
| SCHEMBL29897189 | 0.88 | CASP6 (0.58) | CASP6TSHRHCAR3LMNAMAPT | |
| SCHEMBL4299408 | 0.88 | CASP6 (0.58) | CASP6TSHRHCAR3LMNAMAPT | |
| SCHEMBL17511817 | 0.88 | HCAR3 (0.58) | CASP6TSHRHCAR3LMNAMAPT | |
| SCHEMBL6950169 | 0.85 | CASP6 (0.55) | CASP6TSHRHCAR3LMNAAPEX1 | |
| SCHEMBL16129649 | 0.85 | HCAR3 (0.56) | CASP6TSHRHCAR3LMNAMAPT | |
| SCHEMBL20757 | 0.84 | PDK1 (0.68) | CASP6TSHRHCAR3LMNAKMT2A | |
| SCHEMBL177446 | 0.83 | HCAR3 (0.53) | CASP6TSHRHCAR3LMNA | |
| SCHEMBL14212713 | 0.82 | CASP6 (0.55) | CASP6TSHRHCAR3LMNAAPEX1 | |
| SCHEMBL6180268 | 0.81 | HCAR3 (0.64) | CASP6TSHRHCAR3LMNAAPEX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11622970-B2 | BCL-2 inhibitors and their use as pharmaceuticals | Prelude Therapeutics Incorporation (US) | 2023-04-11 | — | — | US | disclosed |
| US-20210346405-A1 | BCL-2 INHIBITORS AND THEIR USE AS PHARMACEUTICALS | PRELUDE THERAPEUTICS INCORPORATED | 2021-11-11 | — | — | US | disclosed |
| WO-2021222174-A1 | BCL-2 INHIBITORS AND THEIR USE AS PHARMACEUTICALS | PRELUDE THERAPEUTICS INCORPORATED (US) | 2021-11-04 | — | — | WO | disclosed |
| WO-2021222174-A1 | BCL-2 INHIBITORS AND THEIR USE AS PHARMACEUTICALS | PRELUDE THERAPEUTICS INCORPORATED (US) | 2021-11-04 | — | — | WO | disclosed |
| US-10130633-B2 | Compounds | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-11-20 | — | — | US | disclosed |
| EP-2976327-B1 | 3-ACETYLAMINO-1-(PHENYL-HETEROARYL-AMINOCARBONYL OR PHENYL-HETEROARYL-CARBONYLAMINO)BENZENE DERIVATIVES FOR THE TREATMENT OF HYPERPROLIFERATIVE DISORDERS | Bayer Pharma AG (DE) | 2017-06-21 | — | — | EP | disclosed |
| EP-2976327-B1 | 3-ACETYLAMINO-1-(PHENYL-HETEROARYL-AMINOCARBONYL OR PHENYL-HETEROARYL-CARBONYLAMINO)BENZENE DERIVATIVES FOR THE TREATMENT OF HYPERPROLIFERATIVE DISORDERS | Bayer Pharma AG (DE) | 2017-06-21 | — | — | EP | disclosed |
| US-20160263122-A1 | NOVEL COMPOUNDS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-09-15 | — | — | US | disclosed |
| US-20160263122-A1 | NOVEL COMPOUNDS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-09-15 | — | — | US | disclosed |
| US-20160263122-A1 | NOVEL COMPOUNDS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-09-15 | — | — | US | disclosed |
| WO-2008075070-A1 | SULFONAMIDE DERIVATIVES FOR THERAPEUTIC USE AS FATTY ACID SYNTHASE INHIBITORS | ASTRAZENECA AB (SE) | 2008-06-26 | — | — | WO | disclosed |
| US-5753642-A | AGRICULTURE, MEDICINE | ROHM AND HAAS COMPANY (US) | 1998-05-19 | — | — | US | disclosed |
| US-5728698-A | AGRICULTURAL USE, RICE, WHEAT | ROHM AND HAAS COMPANY (US) | 1998-03-17 | — | — | US | disclosed |
| US-5728715-A | FOR MAMMALS, AGRICULTURE, RICE, WHEAT, TOMATOES | ROHM AND HAAS COMPANY (US) | 1998-03-17 | — | — | US | disclosed |
| US-5728694-A | Dihydropyridazinones, pyridazinones and related compounds as fungicides | ROHM AND HAAS COMPANY (US) | 1998-03-17 | — | — | US | disclosed |
| US-5726176-A | FOR CONTROLLING AGRICULTURAL AND MAMMALIAN FUNGAL DISEASES | ROHM AND HAAS COMPANY (US) | 1998-03-10 | — | — | US | disclosed |
| US-5726162-A | FOR CONTROLLING AGRICULTURAL AND MAMMALIAN FUNGAL DISEASES | ROHM AND HAAS COMPANY (US) | 1998-03-10 | — | — | US | disclosed |
| US-5631254-A | RICE; HUMAN INFECTIONS | ROHM AND HAAS COMPANY (US) | 1997-05-20 | — | — | US | disclosed |
| US-5552409-A | PHYTOPATHOGENIC, RICE | ROHM AND HAAS COMPANY (US) | 1996-09-03 | — | — | US | disclosed |
| EP-0478195-A1 | Dihydropyridazinones, pyridazinones and related compounds as fungicides | ROHM AND HAAS COMPANY (US) | 1992-04-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160263122-A1 | NOVEL COMPOUNDS | NAT1, AADAC, CBR3 | CASP6 1557/4885TSHR 1816/4885HCAR3 532/4885 |
| US-20210346405-A1 | BCL-2 INHIBITORS AND THEIR USE AS PHARMACEUTICALS | BCL2, BCL2L2, BCL2L1 | CASP6 36/4885TSHR 3869/4885HCAR3 4362/4885 |
| US-11622970-B2 | BCL-2 inhibitors and their use as pharmaceuticals | BCL2, BCL2L2, BCL2L1 | CASP6 36/4885TSHR 3869/4885HCAR3 4362/4885 |
| US-10130633-B2 | Compounds | AADAC, NAT1, CBR3 | CASP6 1116/4885TSHR 2036/4885HCAR3 379/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.